Ivan Netuka

[Daniel Roberts @danroberts0101]

Childress. Liquid cooling online.

[Daniel Roberts @danroberts0101]

Overnight, $IREN traded almost AUD $10 billion in a single session on the NASDAQ - more than the entire @ASX's on-market daily turnover of AUD $7.5 billion.

I'll be honest. That number is humbling. But it also stings a little.

Because two and a half years ago, we were told we weren't welcome on the ASX.

The rejection was disappointing - not just for what it meant for us as a company, but for what it said about Australia's willingness to back next-generation technology at scale. We believed then, as we do now, that the future of digital infrastructure and compute deserved a place in Australian capital markets. Apparently, the feeling wasn't mutual.

But we never gave up on Australia.

We have continued to try and do business here. We have several large-scale data centre development sites across the country, and our commitment to building world-class, renewable-powered infrastructure on Australian soil has never wavered.

Australia has everything it needs to be a global leader in AI infrastructure - the land, the renewable energy, the engineering talent.

The permitting and regulatory process remains our biggest challenge - and I won't pretend otherwise. It is slow, complex, and at times deeply frustrating for a business operating at the speed that AI demands.

What it needs now is the regulatory and policy environment to not miss out on this opportunity.

But we are working through it, and when we get to the other side, we are ready to accelerate.

[Daniel Roberts @danroberts0101]

Sweetwater 1 energized.
Good to see it coming together, plenty more to do. $IREN

[FreeFromMatrix @ViralMuzik1989]

This is the moment every $IREN investor has been dreaming about since it was first announced in January 21, 2025, when the stock price was still trading at around 10$.

Kudos to @IREN_Ltd , execution is what sets them apart 🫡

[JHLT @TheJHLT]

A UNOS registry analysis of #DCD #HTx with and without use of ex-vivo perfusion device showed that prolonged donor agonal period was associated with higher mortality & acute rejection in no-EHVP grafts, but #EVHP mitigated these risks. @AlexanderB21965

🔗: https://t.co/n9pYWb71GM

[Nir Uriel, MD MSc @NirUrielMD]

Now in @JACCJournals #JACCHF

What is the feasibility of physician-directed patient self management using ambulatory IVC based congestion monitoring ?

Insights from the FUTURE-HFII trial

Link: https://t.co/o48lMC6INm

SimPub @crfheart #THT2026 @FudimMarat

[Ivan Netuka @netuka_ivan]

@midascabal Midas, your comments are worthless, if you happen to even exist

[Ivan Netuka @netuka_ivan]

Immensely proud of our IKEM, Prague junior team for winning once again the 1st Rank in the EACTS MCS 2025 Rising Star Quiz! A combination of solid knowledge and relentless tenacity could bring them to a goal line. Happy to reconvene at the EACTS MCS Summit 2026 in Amsterdam!

[Aditi Nayak @AditiNayakMD]

5/ Other findings:
🛑Disparities in #LVAD utilization disfavoring women and Black pts are amplified in older adults. This, despite older 👵having better 5-yr survival than👴.

Pre-proof available @annalsthorsurg here: https://t.co/r4fpaP4jSh

@TomHanffMD @noshreza @JasonKatzMD

[Aditi Nayak @AditiNayakMD]

4/Other findings:
🔥7-yr survival 52% with #HM3 in all-comers in the real world
➡️3% rescue #RVAD use at 30 days, 5% discharged home on inotropes w #HM3, no change from prior eras
➡️Concomitant #RVAD had better 1-yr survival than rescue #RVAD (69% vs 51%)
@EMDeFilippisMD

[Aditi Nayak @AditiNayakMD]

3/💡for further study:
❓Which 65-69 yr old 🫀 eligible adults would derive survival benefit from #LVAD over a direct to 🫀 strategy? Tools like #HM3 Risk Score and US-CRS to individualize care?
📈Revise pt eligibility and expand #LVAD use in those >=70 yrs if congruent w values

[Aditi Nayak @AditiNayakMD]

2/⚖️Subgroup analyses were performed in the 65-69 yr (transplant eligible) and >=70 yr cohorts, and demonstrated robust survival benefit with the #HeartMate3 regardless of 👫, race, INTERMACS profile, temp #MCS use and psychosocial risk (including social support)
@preventfailure

[Aditi Nayak @AditiNayakMD]

📢The 2025 @STS_CTsurgery #Intermacs Annual Report is here:
👵We addressed the gap in evidence for advanced #HF mgmt in older adults by 🔎on #HeartMate3 outcomes in those >=65 yrs
Major findings:
🏃‍♀️Median survival >5 yrs, 6-mth #NYHA I-II in >50%, low adverse events
Nuances👇

[Ivan Netuka @netuka_ivan]

@NemecekSva @cabanmart More evidence coming soon…

[Martin Čaban @cabanmart]

"Vždy nás zdobily hodnoty (jako) rozpočtová odpovědnost."

Píše někdo, kdo za sebou nechává čtvrtou úhradovou vyhlášku s deficitem, tentokrát už rovnou cca 20 mld.

Lovely.

[Martin Čaban @cabanmart]

Ještě šířeji k té "rozpočtové odpovědnosti" TOP 09:

"Je to finanční granát, který má sílu otřást systémem zdravotního pojištění. Jde o čtvrtou deficitní úhradovou vyhlášku v řadě, přičemž takhle vysoký rozdíl mezi příjmy a výdaji systému dosud nebyl."

https://t.co/1ZBQqzpcLk

[Ivan Netuka @netuka_ivan]

@Tips2Home Idet uae

[Ivan Netuka @netuka_ivan]

@pavelsafr @Sima_Ondra S virtuznim citem nestrannosti. 👍 jen me stve, ze volaji sami novinari, odsuzuji toto nove dno, ale zvednutych hlasu pomalu…🤷‍♂️ navic argumentacne sama dira, ptal se pan Kmenta dotcenych uredniku MZ? A co mu rekli, ze jim volal premier a chtel odvolani manazera level -2? Asi ne.

[Pavel Šafr @pavelsafr]

@Sima_Ondra Představa Jardy Kmenty, jak Petr Fiala vykrádá nějakou nemocnici, je velká legrace. Vždyť Fiala něco takového vůbec neumí 😁 Ale fascinuje mě, že to s Petrem Šabatou s takovým citem naplánovali na dva dny před volbami.